Michael Ulz
Stock Analyst at Morgan Stanley
(4.69)
# 158
Out of 5,126 analysts
103
Total ratings
62.71%
Success rate
33.69%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Ulz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GUTS Fractyl Health | Downgrades: Equal-Weight | $8 → $2 | $0.42 | +381.93% | 3 | Jan 30, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintains: Overweight | $95 → $123 | $100.47 | +22.42% | 6 | Jan 30, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $495 → $408 | $328.16 | +24.33% | 13 | Jan 30, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Equal-Weight | $48 → $81 | $64.52 | +25.54% | 7 | Jan 7, 2026 | |
| DYN Dyne Therapeutics | Maintains: Overweight | $46 → $50 | $16.80 | +197.62% | 3 | Dec 9, 2025 | |
| KYTX Kyverna Therapeutics | Maintains: Overweight | $20 → $25 | $7.93 | +215.26% | 3 | Dec 4, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $90 → $94 | $86.50 | +8.67% | 8 | Oct 30, 2025 | |
| VKTX Viking Therapeutics | Maintains: Overweight | $98 → $102 | $28.44 | +258.65% | 4 | Oct 23, 2025 | |
| KPTI Karyopharm Therapeutics | Maintains: Outperform | $25 → $21 | $6.26 | +235.46% | 8 | Oct 9, 2025 | |
| SLN Silence Therapeutics | Maintains: Overweight | $45 → $25 | $4.75 | +426.32% | 12 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $22 | $2.51 | +776.49% | 6 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $29 | $12.65 | +129.25% | 1 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $20 | $2.53 | +690.51% | 4 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $7 | $1.14 | +514.04% | 8 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $27 | $10.42 | +159.12% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $30 → $20 | $0.93 | +2,049.84% | 3 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $3.16 | +1,324.05% | 1 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $10 | $0.54 | +1,748.77% | 3 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $3 | $4.61 | -34.92% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $18 → $30 | $7.19 | +317.25% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $80 | $24.70 | +223.89% | 3 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $15 | $14.30 | +4.90% | 3 | Jul 12, 2017 |
Fractyl Health
Jan 30, 2026
Downgrades: Equal-Weight
Price Target: $8 → $2
Current: $0.42
Upside: +381.93%
Mirum Pharmaceuticals
Jan 30, 2026
Maintains: Overweight
Price Target: $95 → $123
Current: $100.47
Upside: +22.42%
Alnylam Pharmaceuticals
Jan 30, 2026
Maintains: Equal-Weight
Price Target: $495 → $408
Current: $328.16
Upside: +24.33%
Arrowhead Pharmaceuticals
Jan 7, 2026
Maintains: Equal-Weight
Price Target: $48 → $81
Current: $64.52
Upside: +25.54%
Dyne Therapeutics
Dec 9, 2025
Maintains: Overweight
Price Target: $46 → $50
Current: $16.80
Upside: +197.62%
Kyverna Therapeutics
Dec 4, 2025
Maintains: Overweight
Price Target: $20 → $25
Current: $7.93
Upside: +215.26%
Ionis Pharmaceuticals
Oct 30, 2025
Maintains: Overweight
Price Target: $90 → $94
Current: $86.50
Upside: +8.67%
Viking Therapeutics
Oct 23, 2025
Maintains: Overweight
Price Target: $98 → $102
Current: $28.44
Upside: +258.65%
Karyopharm Therapeutics
Oct 9, 2025
Maintains: Outperform
Price Target: $25 → $21
Current: $6.26
Upside: +235.46%
Silence Therapeutics
May 9, 2025
Maintains: Overweight
Price Target: $45 → $25
Current: $4.75
Upside: +426.32%
Apr 1, 2025
Maintains: Overweight
Price Target: $30 → $22
Current: $2.51
Upside: +776.49%
Mar 10, 2025
Initiates: Overweight
Price Target: $29
Current: $12.65
Upside: +129.25%
Feb 28, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $2.53
Upside: +690.51%
Feb 27, 2024
Maintains: Equal-Weight
Price Target: $3 → $7
Current: $1.14
Upside: +514.04%
Aug 16, 2023
Maintains: Outperform
Price Target: $15 → $27
Current: $10.42
Upside: +159.12%
Mar 24, 2023
Maintains: Equal-Weight
Price Target: $30 → $20
Current: $0.93
Upside: +2,049.84%
Feb 1, 2023
Initiates: Overweight
Price Target: $45
Current: $3.16
Upside: +1,324.05%
Jan 27, 2023
Maintains: Overweight
Price Target: $20 → $10
Current: $0.54
Upside: +1,748.77%
Jan 27, 2023
Downgrades: Equal-Weight
Price Target: $3
Current: $4.61
Upside: -34.92%
Jan 27, 2023
Upgrades: Equal-Weight
Price Target: $18 → $30
Current: $7.19
Upside: +317.25%
Nov 3, 2017
Maintains: Outperform
Price Target: $85 → $80
Current: $24.70
Upside: +223.89%
Jul 12, 2017
Maintains: Outperform
Price Target: $12 → $15
Current: $14.30
Upside: +4.90%